SE0001071D0 - Method of inhibiting the expression of inflammatory cytokines and chemokines - Google Patents

Method of inhibiting the expression of inflammatory cytokines and chemokines

Info

Publication number
SE0001071D0
SE0001071D0 SE0001071A SE0001071A SE0001071D0 SE 0001071 D0 SE0001071 D0 SE 0001071D0 SE 0001071 A SE0001071 A SE 0001071A SE 0001071 A SE0001071 A SE 0001071A SE 0001071 D0 SE0001071 D0 SE 0001071D0
Authority
SE
Sweden
Prior art keywords
chemokines
expression
inflammatory cytokines
man
animal
Prior art date
Application number
SE0001071A
Other languages
English (en)
Swedish (sv)
Inventor
Sven Pettersson
Tove Andersson
Original Assignee
Astacarotene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astacarotene Ab filed Critical Astacarotene Ab
Priority to SE0001071A priority Critical patent/SE0001071D0/xx
Publication of SE0001071D0 publication Critical patent/SE0001071D0/xx
Priority to AT01916022T priority patent/ATE353639T1/de
Priority to JP2001570257A priority patent/JP2003528139A/ja
Priority to CA2405479A priority patent/CA2405479C/en
Priority to EP01916022A priority patent/EP1267857B1/en
Priority to AU2001242965A priority patent/AU2001242965A1/en
Priority to US10/239,192 priority patent/US7078040B2/en
Priority to PCT/SE2001/000600 priority patent/WO2001072296A1/en
Priority to DE60126591T priority patent/DE60126591D1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0001071A 2000-03-27 2000-03-27 Method of inhibiting the expression of inflammatory cytokines and chemokines SE0001071D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE0001071A SE0001071D0 (sv) 2000-03-27 2000-03-27 Method of inhibiting the expression of inflammatory cytokines and chemokines
AT01916022T ATE353639T1 (de) 2000-03-27 2001-03-21 In-vitro-verwendung von astaxanthin zur vorbehandlung von zellen vor uv-bestrahlung zwecks hemmung der aktivierung von nf-kb
JP2001570257A JP2003528139A (ja) 2000-03-27 2001-03-21 炎症性サイトカインおよびケモカインの発現を阻害する方法
CA2405479A CA2405479C (en) 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines
EP01916022A EP1267857B1 (en) 2000-03-27 2001-03-21 In vitro use of astaxanthin for pretreatment of cells prior to UV-exposure to inhibit the activation of NF-kB
AU2001242965A AU2001242965A1 (en) 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines
US10/239,192 US7078040B2 (en) 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines
PCT/SE2001/000600 WO2001072296A1 (en) 2000-03-27 2001-03-21 Method of inhibiting the expression of inflammatory cytokines and chemokines
DE60126591T DE60126591D1 (de) 2000-03-27 2001-03-21 In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0001071A SE0001071D0 (sv) 2000-03-27 2000-03-27 Method of inhibiting the expression of inflammatory cytokines and chemokines

Publications (1)

Publication Number Publication Date
SE0001071D0 true SE0001071D0 (sv) 2000-03-27

Family

ID=20279020

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0001071A SE0001071D0 (sv) 2000-03-27 2000-03-27 Method of inhibiting the expression of inflammatory cytokines and chemokines

Country Status (8)

Country Link
EP (1) EP1267857B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003528139A (cg-RX-API-DMAC7.html)
AT (1) ATE353639T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001242965A1 (cg-RX-API-DMAC7.html)
CA (1) CA2405479C (cg-RX-API-DMAC7.html)
DE (1) DE60126591D1 (cg-RX-API-DMAC7.html)
SE (1) SE0001071D0 (cg-RX-API-DMAC7.html)
WO (1) WO2001072296A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003048202A2 (en) * 2001-12-03 2003-06-12 Asahi Kasei Pharma Corporation Nf-kappab activating genes
EP2653157B1 (en) * 2004-02-04 2016-08-03 Fuji Chemical Industry Co., Ltd. Astaxanthin for improving muscle atrophy
JP2006008714A (ja) * 2005-03-17 2006-01-12 Yamaha Motor Co Ltd マトリックスメタロプロテイナーゼ阻害剤
JP2006008718A (ja) * 2005-06-03 2006-01-12 Yamaha Motor Co Ltd シクロオキシゲナーゼ活性阻害剤
JP2006008719A (ja) * 2005-06-23 2006-01-12 Yamaha Motor Co Ltd 血中過酸化脂質抑制剤
US7805004B2 (en) * 2007-02-28 2010-09-28 Microsoft Corporation Radical set determination for HMM based east asian character recognition
WO2008106606A2 (en) * 2007-02-28 2008-09-04 Cardax Pharmaceuticals, Inc. Carotenoid analogs and derivatives in the treatment of prostate cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05155736A (ja) * 1991-12-10 1993-06-22 Nakano Seiyaku Kk 化粧料
JPH0799924A (ja) * 1993-09-30 1995-04-18 Nippon Suisan Kaisha Ltd アスタキサンチンを主要成分とするファフィア色素油の安定な粉末化物及びその製造方法
JPH07300421A (ja) * 1994-04-28 1995-11-14 Itano Reitou Kk 抗炎症剤
US5527533A (en) * 1994-10-27 1996-06-18 Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US5886053A (en) * 1995-02-03 1999-03-23 Basf Aktiengesellschaft Use of carotenoids for producing drugs for the treatment of dermatoses
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物
JPH09143063A (ja) * 1995-11-22 1997-06-03 Kose Corp 外用に適する組成物
SE522246C2 (sv) * 1997-02-27 2004-01-27 Astacarotene Ab Oralt preparat för profylaktisk och terapeutisk behandling av Helicobacter Sp. infektion
EP0984915A4 (en) * 1997-04-04 2002-11-27 Henkel Corp LUTEINE ESTERS WITH HIGH BIOAVAILABILITY
SE512531C2 (sv) * 1997-09-04 2000-03-27 Astacarotene Ab Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Also Published As

Publication number Publication date
DE60126591D1 (de) 2007-03-29
ATE353639T1 (de) 2007-03-15
CA2405479C (en) 2010-11-16
AU2001242965A1 (en) 2001-10-08
CA2405479A1 (en) 2001-10-04
EP1267857A1 (en) 2003-01-02
WO2001072296A1 (en) 2001-10-04
JP2003528139A (ja) 2003-09-24
EP1267857B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
AR025247A1 (es) Composiciones de granulos de carotenos-xantofilos, estables
YU57600A (sh) Derivarti biciklične hidroksaminske kiseline
FI971412A0 (fi) Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
SE9704870D0 (sv) New pharmaceutical formulation I
ECSP034896A (es) Derivados aromaticos de acidos dicarboxilicos
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CO4290432A1 (es) Nuevos derivados de pirazinacarboxamida, su preparacion y su utilizacion en medicamentos.
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
SE9802208D0 (sv) Novel compounds
DE69034070D1 (de) Racemisches Huperzin A
SE9700885D0 (sv) New pharmaceutical formulation
AU2558300A (en) Substituted stilbene compounds with vascular damaging activity
AU2001242965A1 (en) Method of inhibiting the expression of inflammatory cytokines and chemokines
YU36401A (sh) Farmaceutska kompozicija za stimulator osetljivosti na insulin sa modifikovanim ispuštanjem
ES2174113T3 (es) Nuevos derivados de ((3-alcoxi-fenoxi)-etil)-dialquilamina y su utilizacion como anestesicos locales.
PH27446A (en) Compound with gastric acid inhibitory effect
SE9802209D0 (sv) Novel compounds
AU2002223970A1 (en) Kyberdrug as autovaccines with immune-regulating effects
GEP20043231B (en) Resorcinol Composition
JP2003528139A5 (cg-RX-API-DMAC7.html)
DE69828522D1 (de) Antithrombotische mittel